{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:30:10Z","timestamp":1747801810210,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01400-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T03:28:24Z","timestamp":1745292504000},"page":"1391-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-6968","authenticated-orcid":false,"given":"Adam","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-8541","authenticated-orcid":false,"given":"Georges","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-8279","authenticated-orcid":false,"given":"Yemi","family":"Oluboyede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-5918","authenticated-orcid":false,"given":"Iyar","family":"Mazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-7584","authenticated-orcid":false,"given":"Kristina","family":"Gorbatenko-Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"2","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.10.014.","journal-title":"Autoimmun Rev"},{"key":"1400_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366. https:\/\/doi.org\/10.2147\/CCID.S245649.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806-12.e3. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.035.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","volume":"4","author":"R Abedini","year":"2018","unstructured":"Abedini R, Hallaji Z, Lajevardi V, et al. Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol. 2018;4(2):91\u20134. https:\/\/doi.org\/10.1016\/j.ijwd.2017.07.001.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, et al. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62-s68. https:\/\/doi.org\/10.1016\/j.jisp.2020.05.007.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1400_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1400_CR7","doi-asserted-by":"publisher","unstructured":"Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281-8. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6085.","DOI":"10.1001\/jamadermatol.2022.6085"},{"issue":"4","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/ijt.ijt_53_17","volume":"9","author":"ST Hussain","year":"2017","unstructured":"Hussain ST, Mostaghimi A, Barr PJ, et al. Utilization of mental health resources and complementary and alternative therapies for alopecia areata: a US survey. Int J Trichol. 2017;9(4):160\u20134. https:\/\/doi.org\/10.4103\/ijt.ijt_53_17.","journal-title":"Int J Trichol"},{"issue":"3","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383. https:\/\/doi.org\/10.1007\/s13555-021-00512-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1400_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, et al. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther (Heidelb). 2023;13(1):285\u201398. https:\/\/doi.org\/10.1007\/s13555-022-00864-1.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1400_CR11","doi-asserted-by":"publisher","unstructured":"Mostaghimi A, Soliman AM, Li C, et al. Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata. JAMA Dermatol. 2024;160(9):945-52. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2404.","DOI":"10.1001\/jamadermatol.2024.2404"},{"issue":"12","key":"1400_CR12","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2023","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Farrant P, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther (Heidelb). 2023;13(12):3121\u201335. https:\/\/doi.org\/10.1007\/s13555-023-01057-0","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1400_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaad.2021.06.879","volume":"87","author":"JJ Han","year":"2022","unstructured":"Han JJ, Li SJ, Joyce CJ, et al. Association of resilience and perceived stress in patients with alopecia areata: a cross-sectional study. J Am Acad Dermatol. 2022;87(1):151\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.879.","journal-title":"J Am Acad Dermatol"},{"issue":"10387","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"key":"1400_CR15","unstructured":"Pfizer Inc. FDA approves Pfizer\u2019s LITFULO\u2122 (ritlecitinib) for adults and adolescents with severe alopecia areata. 2023. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and. Accessed 29 Oct 2024."},{"issue":"1","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"KW Wyrwich","year":"2022","unstructured":"Wyrwich KW, Winnette R, Bender R, et al. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb). 2022;12(1):149\u201366. https:\/\/doi.org\/10.1007\/s13555-021-00648-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1400_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00899-4","author":"R Sinclair","year":"2024","unstructured":"Sinclair R, Mesinkovska N, Mitra D, et al. Patient-reported hair loss and its impacts as measured by the Alopecia Areata Patient Priority Outcomes instrument in patients treated with ritlecitinib: the ALLEGRO phase 2b\/3 randomized clinical trial. Am J Clin Dermatol. 2024. https:\/\/doi.org\/10.1007\/s40257-024-00899-4.","journal-title":"Am J Clin Dermatol"},{"key":"1400_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17909","author":"R Winnette","year":"2022","unstructured":"Winnette R, Banerjee A, Sikirica V, et al. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J Eur Acad Dermatol Venereol. 2022. https:\/\/doi.org\/10.1111\/jdv.17909.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s11136-020-02755-4","volume":"30","author":"V S\u00e9bille","year":"2021","unstructured":"S\u00e9bille V, Lix LM, Ayilara OF, et al. Critical examination of current response shift methods and proposal for advancing new methods. Qual Life Res. 2021;30(12):3325\u201342. https:\/\/doi.org\/10.1007\/s11136-020-02755-4.","journal-title":"Qual Life Res"},{"key":"1400_CR20","volume-title":"Quality of Life: The Assessment, Analysis and Reporting of Patient-Reported Outcomes","author":"PM Fayers","year":"2013","unstructured":"Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Reporting of Patient-Reported Outcomes. New York: Wiley; 2013."},{"issue":"2","key":"1400_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11136-010-9737-y","volume":"20","author":"RJ Beeken","year":"2011","unstructured":"Beeken RJ, Eiser C, Dalley C. Health-related quality of life in haematopoietic stem cell transplant survivors: a qualitative study on the role of psychosocial variables and response shifts. Qual Life Res. 2011;20(2):153\u201360. https:\/\/doi.org\/10.1007\/s11136-010-9737-y.","journal-title":"Qual Life Res"},{"key":"1400_CR22","unstructured":"Washington G. Towards creation of a curl pattern recognition system. In: 2018 International Conference on Image Processing, Computer Vision, and Pattern Recognition; 18\u201323 June 2018, Salt Lake City. Las Vegas: CSREA Press, ISBN (1-60132-485-5)."},{"issue":"4","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s13555-022-00702-4","volume":"12","author":"HL Gelhorn","year":"2022","unstructured":"Gelhorn HL, Cutts K, Edson-Heredia E, et al. The relationship between patient-reported severity of hair loss and health-related quality of life and treatment patterns among patients with alopecia areata. Dermatol Ther (Heidelb). 2022;12(4):989\u201397. https:\/\/doi.org\/10.1007\/s13555-022-00702-4.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.5546\/aap.2017.eng.e404","volume":"115","author":"KJ Ju\u00e1rez-Rend\u00f3n","year":"2017","unstructured":"Ju\u00e1rez-Rend\u00f3n KJ, Rivera S\u00e1nchez G, Reyes-L\u00f3pez M, et al. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404-11. https:\/\/doi.org\/10.5546\/aap.2017.eng.e404.","journal-title":"Arch Argent Pediatr"},{"issue":"5","key":"1400_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000530356","volume":"9","author":"L Drake","year":"2023","unstructured":"Drake L, Li SJ, Reyes-Hadsall S, et al. Post-traumatic stress disorder in patients with alopecia areata: a survey study in the USA. Skin Appendage Disord. 2023;9(5):342\u20135. https:\/\/doi.org\/10.1159\/000530356.","journal-title":"Skin Appendage Disord"},{"key":"1400_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15378","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023. https:\/\/doi.org\/10.1111\/pde.15378.","journal-title":"Pediatr Dermatol"},{"issue":"18","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"issue":"3","key":"1400_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"A Tosti","year":"2006","unstructured":"Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2006.05.008.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142.","journal-title":"J Am Acad Dermatol"},{"key":"1400_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01280-3","author":"P Anderson","year":"2024","unstructured":"Anderson P, Piercy J, Austin J, et al. Alopecia areata treatment patterns and satisfaction: results of a real-world cross-sectional survey in Europe. Dermatol Ther (Heidelb). 2024. https:\/\/doi.org\/10.1007\/s13555-024-01280-3.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1400_CR31","unstructured":"Eli Lilly and Company. Highlights of prescribing information. OLUMIANT (baricitinib) tablets, for oral use. 2022.\u00a0https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed 9 Nov 2022."},{"key":"1400_CR32","unstructured":"Pfizer, Inc. Litfulo (ritlecitinib). Prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed March 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01400-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:48:40Z","timestamp":1747759720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01400-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01400-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arash Mostaghimi declares receiving personal fees from Hims & Hers Health, AbbVie, SUN Pharma, Pfizer, Digital Diagnostics, Lilly, Equillium, ASLAN Pharmaceuticals, Boehringer Ingelheim, Acom Healthcare, Olaplex, and Legacy Healthcare. Adam Gibson, Georges Dwyer, and Yemi Oluboyede are employees of Putnam Associates, an independent life sciences consultancy, who were employed by Pfizer to undertake this study. Iyar Mazar and Ernest Law are employees of Pfizer Inc and may own stock and\/or options. Kristina Gorbatenko-Roth declares receiving research and\/or consulting fees from Pfizer, National Alopecia Areata Foundation, and Procter & Gamble.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Participants provided written inform consent prior to entering the study. The study protocol and all participant-facing documentation, including the interview discussion guide, were reviewed by an independent, USA-based ethics review board (Advarra, Inc., Columbia, MD, USA), which deemed the study to be exempt from institutional review board oversight. The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor, and followed generally accepted research practices described in British Healthcare Business Intelligence Association guidelines, UK Data Protection Act 2018, General Data Protection Regulation, and relevant legislations pertaining to data privacy for US participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}